Bimekizumab at different dosing intervals was associated with greater IHS4 improvements at week 48 than placebo in patients with HS.
Katie Notopoulos is a senior correspondent at Business Insider who writes about technology, business, and culture. She covers topics such as internet culture, Big Tech, retail, AI, parenting in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results